Dosecann Launches Industry-Leading, High-Potency Topical: Dosecann Daily Relief CBD Cream

Rhea-AI Summary

Auxly Cannabis Group has launched the Dosecann Daily Relief CBD Cream, a high-strength topical cream containing 1,200mg of CBD per 60 ml unit, making it the most potent CBD topical in Canada. The cream is aimed at providing relief from various symptoms, including pain and inflammation. Developed in Auxly's Charlottetown lab, the product uses a unique formulation to enhance CBD absorption while moisturizing the skin. Available now in British Columbia and Saskatchewan, it will soon launch in Alberta. This product expands Auxly's portfolio in the cannabis 2.0 segment.

Positive

• Launch of Dosecann Daily Relief CBD Cream with 1,200mg of CBD, the highest potency in Canada's market.
• Product priced competitively, aiming to deliver superior value compared to other CBD topicals.
• Developed by a scientific team, ensuring quality and efficacy in formulation.
• High-frequency use segment, as 50% of topical consumers use daily, indicating strong potential market demand.

Negative

• None.

TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Today Dosecann, an in-house brand owned by Auxly Cannabis Group Inc. (TSX - XLY) (“Auxly”), announces the launch of Dosecann Daily Relief CBD Cream, a new, high-strength, differentiated cannabis topical cream for Canadian wellness consumers. With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topicalⁱ. Dosecann Daily Relief CBD Cream is available to order now for wholesalers across Canada, is available to consumers now in British Columbia and Saskatchewan and will also be available in Alberta in coming weeks.

Dosecann Daily CBD Cream was developed by a team of scientists, researchers and formulation experts at Auxly’s state-of-the-art laboratory in Charlottetown, PEI, under the direction of Dr. Bob Chapman, Chief Science Officer, Dosecann.

“Topicals were among the very first products we conceived of at Dosecann and I’m extremely proud that after thorough development and testing, we’ve landed on a formula that we believe is the best in the marketplace,” said Dr. Chapman. “Consumers use topicals to provide daily relief from a wide variety of symptoms such as localized pain relief, muscle soreness, tension and inflammation. Our team was driven to ensure that Dosecann Daily Relief CBD Cream offers industry-leading potency along with a formulation designed to boost CBD penetration and provide the skin moisturizing properties of high-end skin creams.”

“We’re excited to launch Dosecann Daily Relief CBD Cream and expand our expertise in the 2.0 segment into topicals,” said Brad Canario, Brand Director, Auxly. “We know from research that topicals are a high-frequency segment, with nearly 50% of topical consumers using daily, and further, that amongst Canadian cannabis users, creams are the #1 topicals format. We believe we have a truly differentiated product for wellness consumers looking for daily relief from a variety of symptoms and, as always, we focused on our pillars of quality, safety and efficacy at every stage of product development.”

The proprietary Dosecann Daily Relief CBD Cream formula combines high-quality CBD extract with Natralipid™ Meadowfoam seed oil, a plant-based emollient found in high-end skin creams and valued for moisturization, transdermal barrier repair, skin penetration and unsurpassed stability. The result is a product that promotes the fast, effective absorption of high-quality CBD extract so that the cannabinoids can get where they’re needed quickly, all the while soothing the skin by locking-in moisture without leaving a greasy feeling behind. Dosecann Daily Relief CBD Cream has a mild, neutral bamboo scent and is packaged in a recyclable glass jar with a built-in seal to preserve freshness. 

Dosecann Daily Relief CBD Cream is the latest cannabis 2.0 release from Auxly, who achieved the #1 market-share position for Cannabis 2.0 products in 2020. With today’s launch, Dosecann expands its offering of natural, science-backed products, which includes oils and precision-dosed capsules made with omega-rich Ahiflower™ oil.

About Dosecann        
Dosecann is a world-class developer of innovative cannabis products for the wellness-focused consumer, wholly owned by Auxly Cannabis Group Inc. Proudly processed at Auxly’s 52,000 sq. ft., state-of-the-art facility in Charlottetown, Prince Edward Island, Dosecann products are developed and manufactured on-site by a world-class team of scientists and experts, ensuring high-quality, precision and consistency. Dosecann’s wellness products, available at licensed cannabis retailers across Canada, consist of non-GMO capsules and oils. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science.

Learn more at dosecann.com and stay up to date at Twitter: @Dosecann; Instagram: @dosecann; Facebook: @dosecann.

About Auxly Cannabis Group Inc. (TSX: XLY) (OTCQX: CBWTF)        
Auxly is leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly's experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

For more information please contact:
Scott Campbell, 647-402-4957, press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes but is not limited to: Dosecann’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis, cannabis products and cannabis health products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for current and future Dosecann products by consumers and provincial purchasers, and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party sources, the accuracy of which has not been verified by Auxly. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

ⁱ Based on price-per mg of CBD.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/15c477a3-0d65-4413-bd82-f9a849412e2a

FAQ

What is the potency of Dosecann Daily Relief CBD Cream?

Dosecann Daily Relief CBD Cream contains 1,200mg of CBD per 60 ml, making it the most potent CBD topical in Canada's marketplace.

When will Dosecann Daily Relief CBD Cream be available in Alberta?

Dosecann Daily Relief CBD Cream will be available in Alberta in the coming weeks following its launch.

What symptoms can Dosecann Daily Relief CBD Cream help alleviate?

The cream is designed to provide relief from localized pain, muscle soreness, tension, and inflammation.

Who developed the Dosecann Daily Relief CBD Cream?

The cream was developed by a team of scientists and formulation experts at Auxly's laboratory in Charlottetown, PEI.

Is Dosecann Daily Relief CBD Cream environmentally friendly?

Yes, the cream is packaged in a recyclable glass jar with a built-in seal to preserve freshness.